2014
DOI: 10.1002/ajoc.201402109
|View full text |Cite
|
Sign up to set email alerts
|

Synthesis of 19‐Nor‐Vitamin D A‐Ring Synthons via Ring‐Closing Olefin Metathesis

Abstract: 19‐Nor‐vitamin D A‐ring synthons were obtained from linear olefins by means of ring‐closing olefin metathesis followed by palladium‐catalyzed isomerization of the endocyclic olefin product to an exocyclic olefin.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
9
0

Year Published

2016
2016
2020
2020

Publication Types

Select...
7

Relationship

2
5

Authors

Journals

citations
Cited by 8 publications
(9 citation statements)
references
References 36 publications
(14 reference statements)
0
9
0
Order By: Relevance
“…In our effort to delineate VD 3 activity, we initially searched for VD 3 analogs that activate VDR but lack SREBP inhibitory activity. An in-house library of 250 vitamin D congeners was screened for their ability to inhibit the activity of an SREBP-responsive luciferase reporter, in which expression of luciferase is controlled by three SREBP binding sites. We found that a series of vitamin D analogs, bearing alkyltriazole and alkyltetrazole substituents at C2 ( 4 – 9 ) (Figure ), displayed limited SREBP inhibitory activities (Figure A).…”
Section: Resultsmentioning
confidence: 99%
“…In our effort to delineate VD 3 activity, we initially searched for VD 3 analogs that activate VDR but lack SREBP inhibitory activity. An in-house library of 250 vitamin D congeners was screened for their ability to inhibit the activity of an SREBP-responsive luciferase reporter, in which expression of luciferase is controlled by three SREBP binding sites. We found that a series of vitamin D analogs, bearing alkyltriazole and alkyltetrazole substituents at C2 ( 4 – 9 ) (Figure ), displayed limited SREBP inhibitory activities (Figure A).…”
Section: Resultsmentioning
confidence: 99%
“…225) [592]; (10) cyclohexenes, including those employed in syntheses of fluorinated inositol analogs [593], fluorinated cyclohexenes [594], lundurine B (the enol ether was converted to the ketone without isolation) (e.g. 226) [595], sculponeatin N [596], vitamin D derivatives [597], ryanodol (e.g. [598], shikimic acids and pinitol [599], carbasugars [600], madangamine D ( a later step forms a macrocyclic amine via RCM) [601], the kaurene core [602], various securinega alkaloids [603], a labyssomicin C derivative (e.g.…”
Section: )mentioning
confidence: 99%
“…They chose (−)-quinic acid (18) as the starting material since it features the correct hydroxy stereochemistry and is commercially available. Nagasawa's group described [17] a new synthetic method to obtain A-ring synthons 28 (Scheme 5) based on ring-closing metathesis from a linear precursor, and then they applied it to synthesize 1α,25-(OH) 2 -19-nor-D 3 (3a). This strategy enabled the preparation of an A-ring with a more flexible substitution pattern.…”
Section: Synthesis Of 1α25-(oh) 2 -19-nor-vitamin Dmentioning
confidence: 99%